CNR1 and colorectal cancer: Bunsick et al. [6] reported that CB1 agonists can influence both pancreatic and colorectal cancer cellular behavior by modulating GPCR signaling pathways via a functional selectivity mechanism(s), which was found to be essential in regulating cell viability, migration, and epithelial–mesenchymal transition (EMT).